DDMAC issues untitled letter concerning Ista journal ad
In the letter, DDMAC said the journal ad is false or misleading because it fails to reveal material
facts, thus minimizing the risks associated with treatment with Vitrase. "DDMAC requests that Ista immediately cease the dissemination of violative promotional materials for Vitrase," the letter stated.
A spokesperson for Ista was not immediately available for comment.